cfDNA is extremely useful to ascertain chromosomal causes of miscarriages at the point of miscarriage diagnosis by a simple blood test. This study aims to determine the level of cell-free DNA (cfDNA) in early pregnancy and compare the results with those of product of conception (POC) testing, in concordance with standard karyotyping.
Pregnancies achieved by assisted reproductive technologies (ART) are closely monitored, therefore miscarriages that occur very early in the pregnancy are frequently meticulously recorded and reported. On the other hand, spontaneous abortion rates among naturally occurring conceptions are notoriously hard to quantify and are often overstated when using criteria from assisted reproductive technologies. Additionally, women who have undergone treatment with ART are a particular population with traits that can make them more vulnerable to spontaneous abortions. cfDNA would be extremely useful to ascertain chromosomal causes of miscarriages at the point of miscarriage diagnosis by a simple blood test. This study aims to determine the level of cell-free DNA (cfDNA) in early pregnancy and compare the results with those of product of conception (POC) testing, in concordance with standard karyotyping.
Study Type
OBSERVATIONAL
Enrollment
150
This is a routine procedure, no intervention will be provided.
Prince of Wales Hospital
Hong Kong, Hong Kong
RECRUITINGCell-free DNA (cfDNA)
Determine the use of cfDNA to ascertain chromosomal causes of miscarriages
Time frame: 15 weeks
Level of cell-free DNA
To determine the level of cell-free DNA (cfDNA) in early pregnancy
Time frame: 15 weeks
Aneuploidy results from product of conception
To compare the aneuploidy results from product of conception (POC), in concordance with standard karyotyping.
Time frame: 15 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.